Menu

Blog

Archive for the ‘biotech/medical’ category: Page 648

Feb 28, 2023

Tiny Worm Plays a Big Role in Learning Whether Parkinson’s Really Starts in the Gut

Posted by in categories: biotech/medical, neuroscience

Summary: Researchers are utilizing the C. elegnas worm to investigate the emerging theory that Parkinson’s disease starts in the gut and spreads to the brain.

Source: medical college of georgia at augusta university.

A tiny worm called the C. elegans is enabling scientists to explore the emerging theory that Parkinson’s disease starts in the gut.

Feb 28, 2023

Social deficits and seizures in autism genetic subtype tied to overexcited brain circuits

Posted by in categories: biotech/medical, genetics, neuroscience

Northwestern Medicine scientists have identified the cause of a genetic subtype of autism and schizophrenia that results in social deficits and seizures in mice and humans.

Scientists have discovered a key feature of this subtype is a duplicated gene that results in overactive or overexcited brain circuits. The subtype is called 16p11.2 duplication syndrome.

“We found that mice with the same found in humans are more likely to have and also have ,” said lead author Marc Forrest, research assistant professor of neuroscience at Northwestern University Feinberg School of Medicine.

Feb 28, 2023

Computational biology in rare disease research

Posted by in categories: biotech/medical, computing

Rare diseases affect 6–8% of the world’s population and, although we know that small changes in the patient’s DNA are responsible for causing the majority of cases, most people wait several years before they are diagnosed and potentially treated. This hunt for an explanation is extremely distressing for the patients and their families, as well as costing healthcare systems large sums of money for medical investigations and treatments.

Background

Even for the simplest cases, where a single change in a patient’s DNA disrupts a gene and always causes the rare disease, identifying which change in the three billion base pairs in each of our genomes is a huge challenge. Prior to the completion of the human genome in 2003, we did not even know what the normal state of affairs was. Even then, the available sequencing technology limited us to only interrogating small parts of a patient’s genome, directed by intelligent guesswork, with mixed results.

Feb 28, 2023

Dopamine in Fear Extinction

Posted by in categories: biotech/medical, existential risks, neuroscience

The ability to extinguish fear memories when threats are no longer present is critical for adaptive behavior. Fear extinction represents a new learning process that eventually leads to the formation of extinction memories. Understanding the neural basis of fear extinction has considerable clinical significance as deficits in extinction learning are the hallmark of human anxiety disorders. In recent years, the dopamine (DA) system has emerged as one of the key regulators of fear extinction. In this review article, we highlight recent advances that have demonstrated the crucial role DA plays in mediating different phases of fear extinction. Emerging concepts and outstanding questions for future research are also discussed.

Learning to associate stimuli and situations with danger or safety is critical for survival and adaptive behavior. In the laboratory, these forms of learning are typically studied using Pavlovian fear conditioning and extinction. Fear conditioning is an example of associative learning in which an initially neutral stimulus such as a tone (conditioned stimulus, CS) comes to elicit fear responses after being paired in time with an aversive outcome such as a foot shock (unconditioned stimulus, US). Once the CS-US association is learned, subsequently repeated presentations of the CS in the absence of the aversive US result in a gradual decrease in conditioned fear responses, a process known as fear extinction. In the last decades, fear extinction has attracted much interest in part because deficits in extinction learning are thought to underlie human anxiety disorders, such as post-traumatic stress disorder (PTSD) and phobias (Graham and Milad, 2011; Pitman et al., 2012; Craske et al.

Feb 28, 2023

Extracellular Vesicles as “Very Important Particles” (VIPs) in Aging

Posted by in categories: biotech/medical, life extension

In recent decades, extracellular vesicles have been recognized as “very important particles” (VIPs) associated with aging and age-related disease. During the 1980s, researchers discovered that these vesicle particles released by cells were not debris but signaling molecules carrying cargoes that play key roles in physiological processes and physiopathological modulation. Following the International Society for Extracellular Vesicles (ISEV) recommendation, different vesicle particles (e.g., exosomes, microvesicles, oncosomes) have been named globally extracellular vesicles. These vesicles are essential to maintain body homeostasis owing to their essential and evolutionarily conserved role in cellular communication and interaction with different tissues. Furthermore, recent studies have shown the role of extracellular vesicles in aging and age-associated diseases.

Feb 28, 2023

Lab-grown minibrains will be used as ‘biological hardware’ to create new biocomputers, scientists propose

Posted by in categories: biotech/medical, computing

A new proposal suggests using stem cell-derived ‘minibrains’ to create brand-new biocomputers. Such ‘organoid computers’ could be far off, but ethical questions abound.

Feb 28, 2023

A revolutionary new way to store blood for transfusions

Posted by in category: biotech/medical

Year 2014 😗


A new way to easily freeze blood could revolutionise modern medicine.

Feb 28, 2023

Dr. Doug Ethell — Founder & CEO, Leucadia Therapeutics — Diagnosing, Treating & Curing Alzheimer’s

Posted by in categories: biotech/medical, health, neuroscience

Diagnosing, Treating & Curing Alzheimer’s — Dr. Doug Ethell, PhD — Founder & CEO, Leucadia Therapeutics


Dr. Doug Ethell, Ph.D. is Founder and CEO at Leucadia Therapeutics (https://www.leucadiatx.com/), a pre-clinical-stage company focused on diagnosing, treating and curing Alzheimer’s disease.

Continue reading “Dr. Doug Ethell — Founder & CEO, Leucadia Therapeutics — Diagnosing, Treating & Curing Alzheimer’s” »

Feb 28, 2023

Vascular dementia: Could a blood biomarker aid early diagnosis?

Posted by in categories: biotech/medical, neuroscience

A recent study suggests that heightened levels of a biomarker called placental growth factor (PlGF) in a person’s blood may help diagnose vascular dementia in its early stages.

Feb 28, 2023

‘Dead zone’ within tumor promotes cancer spread, helped by a protein secreted by cancer cells

Posted by in category: biotech/medical

A tumor’s necrotic core contains factors that appear to promote metastasis, or the seeding of tumors cells throughout the body, according to a new study in rats by researchers at Fred Hutchinson Cancer Center.

Researchers hope their findings, which will be published the week of Feb. 27 in the Proceedings of the National Academy of Sciences, lead to a better understanding of how to cure metastatic, or stage 4 cancers, which are treatable but not curable.

Continue reading “‘Dead zone’ within tumor promotes cancer spread, helped by a protein secreted by cancer cells” »

Page 648 of 2,688First645646647648649650651652Last